APA (7th ed.) Citation

L, F., T, S., M, F., N, A., L, B., S, S., . . . M, G. (2026). PD-L1 CPS in gastroesophageal cancer: Differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation. British journal of cancer, 135(2), 232. https://doi.org/10.1038/s41416-026-03404-2

Chicago Style (17th ed.) Citation

L, Flanders, et al. "PD-L1 CPS in Gastroesophageal Cancer: Differences in Routine Care Versus Checkmate 649 and Implications for Biopsy-site Choice and Assay Standardisation." British Journal of Cancer 135, no. 2 (2026): 232. https://doi.org/10.1038/s41416-026-03404-2.

MLA (9th ed.) Citation

L, Flanders, et al. "PD-L1 CPS in Gastroesophageal Cancer: Differences in Routine Care Versus Checkmate 649 and Implications for Biopsy-site Choice and Assay Standardisation." British Journal of Cancer, vol. 135, no. 2, 2026, p. 232, https://doi.org/10.1038/s41416-026-03404-2.